What Human Tumor Explant Model Shows

Data from ex vivo testing of fully unaltered human CRC and ovarian cancer tissue material in human tumor explant model indicate that ParvOryx is well suited as a combination partner for cell-based therapies in solid tumors, e.g. CAR-T cell therapies.

What Data Show

Data from two phase 1/2a clinical trials in HR-HPV associated cervical, vulvar, vaginal, penile, anal, head and neck cancers demonstrated the safety of VicOryx and signs of efficacy:

In VicOryx01 clinical trial (NCT01462838) with 26 patients, immune response against p16INK4a antigen was observed in 85% of analyzed patients, as well as objective tumor response in 64% of analyzed patients.

VicOryx01

Publication

In VicOryx02 clinical trial (NCT02526316) with 10 patients, it was shown that VicOryx vaccination is feasible in parallel to cisplatin-based chemotherapy and both immune response against p16INK4a antigen and objective tumor response were observed in 60% of analyzed patients

VicOryx02

Publication

Additionally, data from ongoing follow up-programs in HR-HPV associated cancers show that VicOryx leads to durable objective tumor responses.

What Data Shows

Data from phase 1/2a clinical trial in MSI-H colorectal cancer demonstrated the safety of MicOryx and signs of efficacy:

In MicOryx clinical trial (NCT01461148) with 22 patients, immune response against AIM2(-), HT001(-1) and TAF1B(-1) frameshift peptides was observed in 100% of analyzed patients, as well as objective tumor response in 66% of analyzed patients.

MicOryx

Publication

Additionally, data from ongoing follow up-programs in MSI-H colorectal cancer show that MicOryx leads to durable objective tumor responses.